antibiotics

Dear Research Advocate: Congress has postponed further action on patent reform. Concern over provisions in the legislation poured in from a broad coalition within the life sciences community, including universities, patient advocates, and the pharmaceutical and biotech industries. BIO’s Jim Greenwood and PhRMA’s John Castellani penned a compelling op-ed on the topic for The Hill . Now there is more work to be done as policymakers and advocates continue the conversation about reforming our nation’s patent system. Stay tuned. Momentum for a two-year extension of the R&D tax credit is building in the Senate. The Senate Finance Committee, spearheaded by Senator Orrin Hatch (R-UT), voted...
A global solution and removing barriers to antibiotic development are necessary to combat antimicrobial resistance (AMR). Representatives from various research and health sectors discussed strategies for fighting superbugs at a BIO International Convention super session today. The panel agreed there must be a greater focus on streamlining clinical trials and harmonizing the global regulatory process to support the development of new antibiotics. Jim O'Neill, chairman, Review on Antimicrobial Resistance, recommended the establishment of a global $2 billion AMR Innovation Fund over five years funded by industry to help jump start product development. Venture capitalist risk could stimulate...

Sidebar Quote

Without continued support for health research, many of the most promising young scientists, their ideas and a myriad of potentially life-changing scientific breakthroughs will vanish into oblivion.
Paul Marinec, PhD; University of California San Francisco